MedTrace Logo

Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer

NCT01243372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1142

Last updated 2020-07-24

No results posted yet for this study

Summary

RATIONALE: Studying samples of tissue in the laboratory from patients who received cetuximab may help doctors understand and predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in predicting response to cetuximab in patients with advanced colorectal cancer.

Conditions

Interventions

GENETIC

mutation analysis

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Najjia N. Mahmoud, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2018-01-31
Completion
2018-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243372 on ClinicalTrials.gov